Methodologic aspects of glaucoma phamacogenomic studies.
Christopher T
CT
Leffler
D000287:Administration, Topical; D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use*; D018797:Cell Cycle Proteins; D019389:Cytochrome P-450 CYP2D6 / Q000235:genetics; D003598:Cytoskeletal Proteins / Q000235:genetics; D005136:Eye Proteins / Q000235:genetics; D005838:Genotype; D005901:Glaucoma / Q000188:drug therapy / Q000235:genetics; D006023:Glycoproteins / Q000235:genetics; D006801:Humans; D007429:Intraocular Pressure / Q000187:drug effects* / Q000235:genetics*; D026901:Membrane Transport Proteins; D010597:Pharmacogenetics; D020641:Polymorphism, Single Nucleotide; D018343:Receptors, Adrenergic, beta-2 / Q000235:genetics*; D035582:Transcription Factor TFIIIA / Q000235:genetics; D000099179:Myocilin
D000319:Adrenergic beta-Antagonists; D018797:Cell Cycle Proteins; D019389:Cytochrome P-450 CYP2D6; D003598:Cytoskeletal Proteins; D005136:Eye Proteins; D006023:Glycoproteins; D026901:Membrane Transport Proteins; D018343:Receptors, Adrenergic, beta-2; D035582:Transcription Factor TFIIIA; D000099179:Myocilin; C409460:OPTN protein, human